SEC Filing Summary: Form 8-K
Business Context and Reporting Period
Company: Avista Healthcare Public Acquisition Corp. (AHPAC)
Date of Report: October 5, 2018
Subject: Amendment to the Merger Agreement with Organogenesis Inc.
This filing reports the execution of Amendment No. 1 to the Agreement and Plan of Merger originally entered into on August 17, 2018, between AHPAC, its subsidiary Avista Healthcare Merger Sub, Inc., and Organogenesis Inc. The amendment modifies specific exhibits regarding the corporate charter and bylaws upon domestication but leaves the remainder of the Merger Agreement in full force and effect.
Financial Metrics
This filing is a current report regarding a material definitive agreement and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data for either AHPAC or Organogenesis. The filing text does not provide a clear value for any financial metrics.
Material Changes
- Amendment to Merger Agreement: On October 5, 2018, the parties executed Amendment No. 1 pursuant to Section 9.11 of the original Merger Agreement.
- Specific Modifications: The amendment replaces the "Form of Parent Charter upon Domestication" (Exhibit E) and the "Form of Parent Bylaws upon Domestication" (Exhibit F) attached to the original agreement.
- Continuity: Aside from the specified modifications, the original Merger Agreement remains unchanged and in full force.
Outlook, Risks, and Management Commentary
Forward-Looking Statements: The filing includes standard disclaimers regarding forward-looking statements related to the proposed business combination. These statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations.
Key Risks Identified:
- Termination of the Merger Agreement due to unforeseen events or failure to obtain stockholder approval.
- Inability to meet NASDAQ listing standards.
- Operational disruption to Organogenesis resulting from the transaction announcement and consummation.
- Failure to recognize anticipated benefits due to competition, growth management, or retention of key employees.
- Transaction-related costs and changes in applicable laws or regulations.
Additional Information: AHPAC has filed a registration statement on Form S-4 and a consent solicitation/proxy statement/prospectus. Shareholders are advised to review these documents for detailed information regarding the business combination.
Key Facts for Investor Verification
- Verify the specific changes made to the Parent Charter and Bylaws in the full text of Amendment No. 1 (Exhibit 2.1).
- Review the definitive consent solicitation/proxy statement/prospectus for details on the transaction terms and voting procedures.
- Confirm the status of stockholder approval requirements and the timeline for the proposed business combination.
- Assess the risks associated with the domestication process and the ability of the combined entity to meet NASDAQ listing standards.